report_lead_image_with_gradient.png
Q2 2025

Biopharma VC Trends

Download this Report
To download this report, please complete the form below

VC investment in biopharma declines 40% in Q2

Biopharma startups attracted $5.4 billion in VC funding across 198 deals in Q2. Both figures are multiyear lows, as headwinds continue to weigh on the sector. A general risk-off sentiment has cooled interest in high-risk preclinical assets, stalling seed and early-stage dealmaking, while limited IPO opportunities are placing pressure on maturing startups. Investors are exhibiting caution, prioritizing clinical-stage assets and AI technologies that offer to reduce development timelines and cost. The top deals of the quarter included Pathos’ $365 million Series D and NewLimit, which raised $130 million to extend lifespan with cellular reprogramming.

Exit activity in Q2 highlighted divergent trends between US and Asia-Pacific biopharma markets. For the first time in our data, no US biopharma startup completed an IPO in the quarter, compared with China and South Korea, which saw three public listings each. Even with momentum in Asia-Pacific, only 14 companies have gone public globally through Q2, putting the year on pace to fall well short of the 2020-2024 annual average of 83. With IPO opportunities limited, M&A activity has been robust and is likely to remain a key driver of liquidity going forward.


Table of contents
Biopharma landscape 3
Biopharma VC ecosystem market map 4
VC activity 5
Biopharma VC deal summary 21